Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review

@article{Balak2012CutaneousAE,
  title={Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review},
  author={D. Balak and G. Hengstman and Aysun Çakmak and H. B. Thio},
  journal={Multiple Sclerosis Journal},
  year={2012},
  volume={18},
  pages={1705 - 1717}
}
  • D. Balak, G. Hengstman, +1 author H. B. Thio
  • Published 2012
  • Medicine
  • Multiple Sclerosis Journal
  • Glatiramer acetate and interferon-beta are approved first-line disease-modifying treatments (DMTs) for multiple sclerosis (MS). DMTs can be associated with cutaneous adverse events, which may influence treatment adherence and patient quality of life. In this systematic review, we aimed to provide an overview of the clinical spectrum and the incidence of skin reactions associated with DMTs. A systematic literature search was performed up to May 2011 in Medline, Embase, and Cochrane databases… CONTINUE READING
    49 Citations

    Paper Mentions

    Interventional Clinical Trial
    Purpose of study is to determine safety and efficacy of use of autologous Adipose-Derived cellular Stromal Vascular Fraction (AD-cSVF) suspended in Normal Saline and delivered via… Expand
    ConditionsAutoimmune, Multiple Sclerosis
    InterventionDevice, Procedure
    Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis
    • 16
    • Highly Influenced
    • PDF
    Interferon-beta injection site reactions in patients with multiple sclerosis
    • 2
    Patterns of local site reactions to subcutaneous glatiramer acetate treatment of multiple sclerosis: a clinicopathological study.
    • 1
    • PDF
    Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis
    • 19
    The heritage of glatiramer acetate and its use in multiple sclerosis
    • 9

    References

    SHOWING 1-10 OF 142 REFERENCES
    Interferon in relapsing-remitting multiple sclerosis.
    • 152